Ensysce Biosciences (ENSCW) Income from Non-Controlling Interests (2020 - 2025)
Ensysce Biosciences (ENSCW) reported Income from Non-Controlling Interests of -$166.0 for Q2 2025, down 124.32% quarter-over-quarter from -$74.0 in Q1 2024.
Ensysce Biosciences (ENSCW) Income from Non-Controlling Interests (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 6 years of Income from Non-Controlling Interests data on file, last reported at -$166.0 in Q2 2025.
- Income from Non-Controlling Interests for Q2 2025 came in at -$166.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was -$166.0 (up 84.02% YoY), and the FY2024 annual result was -$74.0, up 99.44% from the prior year.
- Income from Non-Controlling Interests declined to -$166.0 in Q2 2025 per ENSCW's latest filing, from -$74.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $12226.0 in Q4 2022 and troughed at -$35948.0 in Q3 2021.
- A 5-year average of -$7930.3 and a median of -$2588.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2022 and 2023: Income from Non-Controlling Interests jumped 5813.08% in 2022, then sank 2265.38% in 2023.
- A 5-year view of Income from Non-Controlling Interests shows it stood at -$214.0 in 2021, then jumped by 5813.08% to $12226.0 in 2022, then plunged by 107.89% to -$965.0 in 2023, then surged by 92.33% to -$74.0 in 2024, then sank by 124.32% to -$166.0 in 2025.
- Business Quant data shows ENSCW's Income from Non-Controlling Interests at -$166.0 in Q2 2025, -$74.0 in Q1 2024, and -$965.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -166.00 |
| Mar 31, 2024 | -74.00 |
| Dec 31, 2023 | -965.00 |
| Sep 30, 2023 | -1,235.00 |
| Jun 30, 2023 | -7,060.00 |
| Mar 31, 2023 | -3,941.00 |
| Dec 31, 2022 | 12,226.00 |
| Sep 30, 2022 | -21,492.00 |
| Jun 30, 2022 | -26,309.00 |
| Mar 31, 2022 | 182.00 |
| Dec 31, 2021 | -214.00 |
| Sep 30, 2021 | -35,948.00 |
| Jun 30, 2021 | -22,067.00 |
| Mar 31, 2021 | -3,961.00 |
| Dec 31, 2020 | -195,655.00 |
| Sep 30, 2020 | -20,014.00 |
| Jun 30, 2020 | -1,976.00 |